Ohio HB324 establishes the Patient Protection Act, prohibiting the sale of drugs with severe adverse effects impacting over 5% of users.

Ohio HB324, known as the Patient Protection Act, mandates that drugs causing severe adverse effects in more than five percent of users cannot be sold by mail, retailers, or terminal distributors. Wholesale distributors are also prohibited from selling such drugs by mail. Prescribers must conduct an in-person examination and inform patients of the risks before issuing prescriptions for these drugs. The director of health is tasked with determining which drugs meet these criteria, consulting with relevant state boards and the FDA, and maintaining a public list of affected drugs.

Ohio HB324 establishes the Patient Protection Act, prohibiting the sale of drugs with severe adverse effects impacting over 5% of users.

Ohio HB324, known as the Patient Protection Act, mandates that drugs causing severe adverse effects in more than five percent of users cannot be sold by mail, retailers, or terminal distributors. Wholesale distributors are also prohibited from selling such drugs by mail. Prescribers must conduct an in-person examination and inform patients of the risks before issuing prescriptions for these drugs. The director of health is tasked with determining which drugs meet these criteria, consulting with relevant state boards and the FDA, and maintaining a public list of affected drugs.